行情

SGMO

SGMO

SANGAMO THERAPEU
NASDAQ

实时行情|Nasdaq Last Sale

7.50
-0.51
-6.37%
盘后: 7.55 +0.05 +0.67% 19:16 01/24 EST
开盘
8.06
昨收
8.01
最高
8.10
最低
7.39
成交量
267.50万
成交额
--
52周最高
13.91
52周最低
6.26
市值
8.70亿
市盈率(TTM)
-6.8468
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SGMO 新闻

  • Is Sangamo Therapeutics's (NASDAQ:SGMO) Share Price Gain Of 129% Well Earned?
  • Simply Wall St..4天前
  • Big Pharma Remains Accused of Keeping Prices High. That Won’t Change Soon.
  • Barrons.com.01/16 15:34
  • Top Picks 2020- Sangamo Therapeutics SGMO
  • MoneyShow.01/13 10:00
  • Sangamo Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
  • Business Wire.01/09 13:30

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

SGMO 简况

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.
展开

Webull提供Sangamo Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。